RFA-IP-22-004: US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings
Closed
This grant is closed. A newer notice from the same program is open now: NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) (PA-27-100). Status: Due dates in the notice, expires April 5, 2027. It is in our archive of Centers for Disease Control and Prevention - ERA notices from 2022.
Centers for Disease Control and Prevention - ERA offered grants of up to $9.1 million (at least $2.0 million) to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. It expected to make about 8 awards worth $108 million in total. Applications closed on May 9, 2022.
From the official notice on Grants.gov, last changed March 17, 2022. Checked November 7, 2026.
- Award ceiling$9.1 million
- Award floor$2.0 million
- Total funding$108 million
- Expected awards8
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | March 8, 2022 |
|---|---|
| Deadline | May 9, 2022 |
| Archived by Grants.gov | June 8, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
N/A
Is this a realistic fit?
- Most of the money in the 2 programs behind this notice (50% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
Influenza and other respiratory illnesses, including COVID-19, are important causes of morbidity, mortality, and healthcare burden across all age groups. For influenza and novel vaccines, such as for COVID-19, estimates of vaccine effectiveness in preventing illness and associated complications are needed in order to evaluate the protection provided by nationwide vaccination programs. The goal of this notice of funding opportunity is to support a network of US institutions that can: a) conduct systematic testing for laboratory-confirmed disease due to influenza, SARS-CoV-2 and other respiratory virus infections, b) obtain reliable vaccination information for enrolled patients and c) provide accurate estimates of the effectiveness of vaccines against respiratory viruses, including influenza and SARS-CoV-2 and other respiratory viruses, to prevent medically attended influenza-associated illness in the population for whom vaccination is recommended.
Who has won Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects grants before
From fiscal 2021 to 2025, Immunization Research, Demonstration, Public Information and Education Training and Clinical Skills Improvement Projects (93.185) awarded $857 million across 243 grant awards, an average of $3.5 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Unicef | New York | 2 | $133 million |
| National Foundation for the Centers for Disease Control & Prevention, Inc. | Georgia | 2 | $74.7 million |
| Community Catalyst Inc | Massachusetts | 1 | $39.4 million |
| Pan American Health Organization | District of Columbia | 3 | $21.9 million |
| Unidosus | District of Columbia | 1 | $18.6 million |
Who has won Prevention of Disease, Disability, and Death through Immunization and Control of Respiratory and Related Diseases grants before
From fiscal 2021 to 2025, Prevention of Disease, Disability, and Death through Immunization and Control of Respiratory and Related Diseases (93.083) awarded $58.2 million across 30 grant awards, an average of $1.9 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Council of Medical Specia | Illinois | 1 | $40.4 million |
| Post-Acute and Long-Term Care Medical Association, Inc. | Maryland | 1 | $7.1 million |
| National Health Laboratory Service | 1 | $3.1 million | |
| All India Institute of Medical Sciences | 1 | $1.0 million | |
| American Cancer Society, Inc | Georgia | 2 | $900,000 |
Applying now
This notice no longer takes applications. Apply under the newer notice, PA-27-100, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-IP-22-004 still open?
No. It closed on May 9, 2022. A newer notice is open: PA-27-100, due dates in the notice, expires April 5, 2027.
Who can apply for US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings?
Centers for Disease Control and Prevention - ERA accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings?
Closed May 9, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $9.1 million each. About $108 million in total across about 8 awards.
Who has won Prevention of Disease, Disability, and Death through Immunization and Control of Respiratory and Related Diseases grants before?
The largest recipients over five fiscal years were Council of Medical Specia, Post-Acute and Long-Term Care Medical Association, Inc., National Health Laboratory Service. The program made 30 awards worth $58.2 million in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)